Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $350 from $348 and keeps a Buy rating on the shares. The firm, which is updating its model to reflect Q1 results, maintains its “positive conviction” on what it identifies as its top Midcap Biotech stock pick.